Abstract
The role of monamine oxidase (MAO), type A and B, on the deamination of dopamine in the striatum, nucleus accumbens and frontal cortex of the rat was studied. Levels of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) tissue were quantified by means of high pressure liquid chromatography with electrochemical detection. Rats were given pargyline (75 mg/kg), selegyline (5 mg/kg) or clorgyline (2 mg/kg) by the intraperitoneal route, 60 min before sacrifice; in another set of experiments, clorgyline (2 mg/kg, i.p.) was given 15 or 30 min before sacrifice. Only clorgyline and pargyline were found to reduce significantly the formation of DOPAC and HVA in all the three areas of brain under study (83-97% reduction). The inhibition of deamination of dopamine by clorgyline and pargyline was accompanied by an increase in levels of dopamine in tissue. The increase of the levels of amine in tissue, as a result of inhibition of MAOA was more marked in the frontal cortex (52% increase) and the accumbens (39% increase), than in the striatum (25% increase). The results suggest that a substantial amount of DOPAC in brain derives from the deamination of dopamine by MAOA.
References
Sep 1, 1979·Journal of Neurochemistry·J DedekJ Korf
Jan 14, 1976·Naunyn-Schmiedeberg's Archives of Pharmacology·P C WaldmeierL Maître
Oct 1, 1990·Neuropharmacology·P Soares-da-Silva, M C Garrett
Apr 1, 1986·Journal of Neurochemistry·T KatoH Kinemuchi
Aug 1, 1989·Neuropharmacology·D Hovevey-SionD S Goldstein
Apr 15, 1985·Biochemical Pharmacology·J W Commissiong
Feb 1, 1987·The Journal of Pharmacy and Pharmacology·P Soares-da-Silva
May 15, 1987·Biochemical Pharmacology·T B Nguyen, M Angers
Apr 13, 1988·European Journal of Pharmacology·T ZetterströmU Ungerstedt
Mar 1, 1986·Journal of Neurochemistry·K Racké, E Muscholl
Jan 1, 1987·Naunyn-Schmiedeberg's Archives of Pharmacology·K RackéE Muscholl
Mar 17, 1987·European Journal of Pharmacology·B H WesterinkH Koning
Sep 1, 1985·Journal of Neurochemistry·A J AzzaroS Schochet
May 1, 1984·Journal of Neurochemistry·B H WesterinkE Wirix
Dec 9, 1982·Brain Research·B H Westerink, S J Spaan
Citations
Jul 19, 1991·Brain Research·S Puglisi-AllegraS Cabib
Aug 7, 1992·Brain Research·S Kaakkola, R J Wurtman
Oct 28, 1996·Brain Research·D A Di MonteJ W Langston
Jan 1, 1994·Brain Research Bulletin·S HattoriH Nishino
Oct 24, 1996·European Journal of Pharmacology·S ChoM Hadjiconstantinou
Mar 7, 1998·Life Sciences·J T Guimarães, P Soares-da-Silva
Nov 5, 1999·Pharmacology, Biochemistry, and Behavior·C CohenD J Sanger
Jun 23, 2000·Behavioural Brain Research·S CabibD Maestripieri
Mar 14, 2001·Brain Research. Molecular Brain Research·J P PepperR B Rothman
Nov 28, 2002·Neuroscience·R VenturaS Puglisi-Allegra
Jan 1, 1992·British Journal of Pharmacology·J SembaG Curzon
Jan 1, 1991·Acta Neurologica Scandinavica. Supplementum·L Oreland
Jan 1, 1992·Journal of Neurochemistry·M C Garrett, P Soares-da-Silva
May 20, 1999·Journal of Affective Disorders·O CuretB Scatton
Jul 17, 1999·Brain Research·W F MaragosR J Jakel
Jan 31, 2003·Synapse·Wynne K SchifferStephen L Dewey
Jan 19, 2007·The European Journal of Neuroscience·Karine GuillemLuis Stinus
Oct 9, 2009·Nutrition·Alex K LeeSandra D O'Dell
Jun 14, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Daniel I Brierley, Colin Davidson
Jul 5, 2016·Neurochemistry International·Lorenzo Antonio JustoLilian Rosana F Faro
Sep 11, 2012·Neuropharmacology·Ingrid MoralesManuel Rodriguez
Sep 10, 2016·Frontiers in Human Neuroscience·Rebecca A Lundwall, Claudia G Rasmussen
Dec 17, 2016·Neurotoxicity Research·Zhaofei YangXiaomin Wang
Jan 26, 2018·Scientific Reports·Jickssa M GemechuAnna Moszczynska